Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) ...

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...

Michael Moye, President and General Manager of Idorsia US, commented: "The fact that the FDA has expedited the approval of ...

Allschwil, Switzerland - March 27, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 - consisting of the Business Report, Governance Report, Compensation ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report, ...

Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report, Governance Report, Compensation Report, Sustainability Report, and ...

In a report released on March 17, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), with a price target of CHF2.20. The company’s shares ...